Blog
Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple Myeloma
The CAR T-cell therapy idecabtagene vicleucel (ide-cel; Abecma) continues to
June 30, 2021
BLOG
Blog
Alternative oxidase (AOX)
Alternative oxidase (AOX) has been identified as a potential therapeutic
June 28, 2021
Blog
First CAR-T therapy to target BCMA gets FDA nod – Nature
The first CAR-T immunotherapy directed against BCMA (idecabtagene vicleucel) for
June 15, 2021
Blog
Australian Vaccine First In World To Show Ability To Totally Block Covid-19 Virus Transmission
Australian company, Vaxine Pty Ltd, has developed a protein-based COVID-19
May 29, 2021
Blog
Clinical Update: TALEN-Edited CAR T-Cell Therapy for Large B-Cell Lymphoma
ALLO-501A is a CAR T cell-based therapy for relapsed or
May 19, 2021
Blog
Prime editing enables more precise correction of genetic problems than traditional CRISPR
According to scientists at the Medical College of Georgia, a
May 5, 2021
Blog
Design of T Cell Circuits that Sense Antigen Density to Treat Solid Tumors
The development of CAR T cells is one of the
April 7, 2021
Blog
mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma
Multiple myeloma is the second most common hematological malignancy in
April 1, 2021
Blog
Promising Data From First-Ever CRISPR Phage Therapy Trial
Locus Biosciences announced that it has completed the world’s first
March 22, 2021